Pharmaceutical Business review

Catalent names new interim president and CEO

John Lowry, the incumbent in this role, is leaving Catalent to pursue other opportunities, and the search for a replacement is now under way, the company said.

Mr Fotiades has served as chairman of the board since Catalent’s creation in 2007, and will continue to serve in that capacity. Mr Lowry will be assisting Mr Fotiades during the leadership transition.

Mr Fotiades said: “I would like to recognize John Lowry’s important contributions to Catalent over the last seven years, and particularly the leadership continuity and focus he brought during our transition to a standalone company. I am also pleased to assume an even more active role during this transition to help drive Catalent’s future success.”